# T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

> **NCT06343311** · PHASE1,PHASE2 · RECRUITING · sponsor: **Estrella Biopharma, Inc.** · enrollment: 21 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin's Lymphoma (NHL)
- Lymphoma, Non-Hodgkins
- Lymphomas Non-Hodgkin's B-Cell
- Non-Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
- Large B-Cell Lymphoma
- Lymphoma, Non-Hodgkin's, Adult
- Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Lymphoma, Non-Hodgkin
- HIV Associated Lymphoma
- CNS Lymphoma
- High-grade B-cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** EB103

## Key facts

- **NCT ID:** NCT06343311
- **Lead sponsor:** Estrella Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343311, "T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06343311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*